NASA’s Artemis II mission to on board Opella’s Dulcolax for lunar orbit mission

A brand from Opella will be part of the official NASA astronaut formulary

Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer

Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival

Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM

Hester Biosciences appoints Ashish Desai as CFO

Desai is currently serving the company as Group Finance Controller

HRV Pharma unveils brand mascots

Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)

He has been associated with the Zydus Group since 2009

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008

Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg

Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets